How far is Omicron vaccine from sales? Last June165438+1October, Omicrons gradually spread all over the world and became the main group. On February 9th, 65438, Sinopharm Group China Bio and Kexing Kexing introduced Omicron mutant strain from Hongkong University at the same time, and started the product development of Omicron mutant vaccine.
Xie, vice president of Shanghai Institute of Major Infectious Diseases and Biosafety, introduced in detail that at present, the Omicron mutant vaccines of the two companies still use the same eradication technology as the previous COVID-19 vaccine, so the clinical research will be faster. The next step is the "immune relay" test to prove the protection level of the vaccine. He predicted that if all goes well, the funds will be put into use within 2-3 months.
Robert Side, head of the China Laboratory of Skin Allergy and Infectious Diseases in the United States, said, "This means that everyone can still cover up the combination found at this stage by strengthening the current vaccine." Moderna revealed last Tuesday that they and Pfizer are both testing a new bivalent vaccine, which is a mixture of the original COVID-19 vaccine and Omicron targeted therapy vaccine. Mardner said that this bivalent vaccine, which includes 32 gene mutations of Omicron, can better protect Omicron virus-infected people, and its test results will be released at the end of June.
Xie pointed out that it is difficult to predict and analyze the future development trend of COVID-19, so it is impossible to distinguish which way is a better solution. At this stage, it is still very important to do a good job of injecting existing vaccines. The main cause of this epidemic in Shanghai is Omicron BA.2 mutant. On 25th, according to the notification from Yantai City, Shandong Province, and according to high-throughput sequencing, it was found that the virus gene of local virus-infected people was an evolutionary branch of Omicron BA.2.3, which was the first time in China. Just considering the constant variation of COVID-19, it is suggested to develop and design a broad-spectrum vaccine to solve COVID-19 once and for all.
Xie said that COVID-19 vaccination and subsequent intensive vaccination are still reasonable measures to reduce critical illness and mortality, especially for the elderly and high-risk objects with basic diseases. At this stage, WHO strongly supports flexible homologous and heterologous vaccine injection programs. For this matter, Xie feels that it is reasonable whether it comes from the same family or different sources. If you have a vaccine, you can inject it as soon as possible according to your own situation.